尤瑞克林和巴曲酶治疗进展性脑梗死疗效观察

目的:观察尤瑞克林和巴曲酶对进展性脑梗死的疗效。方法:进展性脑梗死患者94例,随机分为尤瑞克林组25例,巴曲酶组28例,联合组11例,对照组30例,均给予神经内科常规治疗,尤瑞克林组加用尤瑞克林,巴曲酶组加用巴曲酶,联合组同时加用尤瑞克林和巴曲酶。观察治疗14、28 d后神经功能缺损评分变化。结果:对照组于治疗14、28 d后神经功能缺损评分与治疗前比较无统计学差异。治疗14 d后尤瑞克林组显效率为12%,巴曲酶组为7.14%,联合组为27.27%,3组间无统计学差异。治疗28 d后尤瑞克林组显效率为36%,巴曲酶组为28.57%,联合组为45.45%,3组间无统计学差异。结论:尤瑞克林和巴曲酶对进展性脑梗死均有较好的疗效,联合应用疗效是否更佳还有待观察。

Urinary Kallidinogenase and Batroxobin Treatment of Progressive Cerebral Infarction

Objective:To observe the therapeutic effect of Urinary kallidinogenase in combination with batroxobin on progressive stroke.Methods:Ninety-four patients with progressive cerebral infarction were assigned into Urinary kallidinogenase group(25 cases),batroxobin group(28 cases),combined treatment group(11 cases) and control group(30 cases).All patients have been treated with the conventional neurological treatment.The neurological function was evaluated 14 days and 28 days after treatment.Results:There was no significant improvement of neurological function in control group 14 days and 28 days after the treatment.On 14 days after treatment,the efficiencys in Urinary kallidinogenase,batroxobin and combined groups were 12%,7.14% and 27.27%,without any difference among the groups.On 28 days,the efficiency of Urinary kallidinogenase group increased to 36%,but no significant difference was observed relative to 28.57% and 45.45% in the other two groups.Conclusion:Both Urinary kallidinogenase and batroxobin show effectiveness on progressive stroke.Whether the combined group has a better effect needs further studies.